about
Immune Cells in Cancer Therapy and Drug DeliveryExploiting IL-17-producing CD4+ and CD8+ T cells to improve cancer immunotherapy in the clinicMigrastatin analogues inhibit canine mammary cancer cell migration and invasionA role of ghrelin in canine mammary carcinoma cells proliferation, apoptosis and migration.β-catenin and PI3Kδ inhibition expands precursor Th17 cells with heightened stemness and antitumor activity.MDSCs mediate angiogenesis and predispose canine mammary tumor cells for metastasis via IL-28/IL-28RA (IFN-λ) signaling.CA 15-3 cell lines and tissue expression in canine mammary cancer and the correlation between serum levels and tumour histological grade.Expression and role of PGP, BCRP, MRP1 and MRP3 in multidrug resistance of canine mammary cancer cells.Macrophages mediate a switch between canonical and non-canonical Wnt pathways in canine mammary tumors.Th17 cells are refractory to senescence and retain robust antitumor activity after long-term ex vivo expansion.Canine mammary carcinoma cell line are resistant to chemosensitizers: verapamil and cyclosporin A.PI3Kδ Inhibition Enhances the Antitumor Fitness of Adoptively Transferred CD8+ T CellsHuman CD26high T cells elicit tumor immunity against multiple malignancies via enhanced migration and persistence.Effect of β-hydroxy-β-methylbutyrate on miRNA expression in differentiating equine satellite cells exposed to hydrogen peroxide.Adoptive cell transfer: new perspective treatment in veterinary oncologySimultaneous miRNA and mRNA Transcriptome Profiling of Differentiating Equine Satellite Cells Treated with Gamma-Oryzanol and Exposed to Hydrogen PeroxideDensity of tumor-associated macrophages (TAMs) and expression of their growth factor receptor MCSF-R and CD14 in canine mammary adenocarcinomas of various grade of malignancy and metastasis
P50
Q26747061-9A36F60C-ABFC-4C88-88E3-305EB629E199Q28075992-9BC02ACE-744B-40BD-9091-E2EA065EEB82Q28534220-C0013E6B-F5D4-4F0E-AD2F-FE782BE49EB5Q31100044-3074D310-E1D1-42B7-BA60-1C5A3F322094Q33578997-13C30E99-C6C5-4114-8372-BCCEFBDED3E3Q33975551-9624E30E-2DFA-457E-B8C0-0DF2A82C4B79Q34315017-9FC20A33-8762-4B77-9CAA-F3E9DC8F8458Q34774983-CC75E18B-BB55-4816-8A0A-AB588192A7C3Q37431430-687FDF0E-E494-4C48-848A-09713F02A59FQ37677403-7AD035EF-C483-4CFC-9C26-D0D6032D911FQ39005191-148E0389-C130-442E-9BC1-BD85D43E4163Q42369747-2F78DE0F-3212-409C-BD55-C1B22B7065CCQ47094002-165B7B93-39EB-4887-BD64-62A83AB660C6Q55033698-1AE8D02F-097F-45CA-B0E8-D5BD0C9CF39EQ57279498-0C14DF18-EB01-4D16-87E6-11EEB18719CAQ60921739-A4AF4BBE-5B63-4BA2-8E29-9B74E9594B36Q83996082-214A23BD-21D2-4A86-94F7-7BB3DDD010BC
P50
description
Pools onderzoekster
@nl
hulumtuese
@sq
researcher
@en
հետազոտող
@hy
name
Kinga Majchrzak
@ast
Kinga Majchrzak
@ca
Kinga Majchrzak
@cs
Kinga Majchrzak
@en
Kinga Majchrzak
@es
Kinga Majchrzak
@gl
Kinga Majchrzak
@hr
Kinga Majchrzak
@hsb
Kinga Majchrzak
@it
Kinga Majchrzak
@nl
type
label
Kinga Majchrzak
@ast
Kinga Majchrzak
@ca
Kinga Majchrzak
@cs
Kinga Majchrzak
@en
Kinga Majchrzak
@es
Kinga Majchrzak
@gl
Kinga Majchrzak
@hr
Kinga Majchrzak
@hsb
Kinga Majchrzak
@it
Kinga Majchrzak
@nl
prefLabel
Kinga Majchrzak
@ast
Kinga Majchrzak
@ca
Kinga Majchrzak
@cs
Kinga Majchrzak
@en
Kinga Majchrzak
@es
Kinga Majchrzak
@gl
Kinga Majchrzak
@hr
Kinga Majchrzak
@hsb
Kinga Majchrzak
@it
Kinga Majchrzak
@nl
P106
P1153
26531687900
P1412
P1559
Kinga Majchrzak
@pl
P21
P27
P31
P496
0000-0002-9504-4588